1921
Volume 102, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Subarachnoid neurocysticercosis (SUBNCC) is usually caused by an aberrant proliferative form of causing mass effect and arachnoiditis. Thirty of 34 SUBNCC patients were treated with extended cysticidal and anti-inflammatory regimens and followed up a median of 4.2 years posttreatment (range: 15 for ≥ 4 years, 20 ≥ 2 years, 26 > 1 year, and 3 < 1 year). The median ages at the time of first symptom, diagnosis, and enrollment were 29.7, 35.6, and 37.9 years, respectively; 58.8% were male and 82.4% were Hispanic. The median time from immigration to symptoms (minimum incubation) was 10 years and the estimated true incubation period considerably greater. Fifty percent also had other forms of NCC. Common complications were hydrocephalus (56%), shunt placement (41%), infarcts (18%), and symptomatic spinal disease (15%). Thirty patients (88.2%) required prolonged treatment with albendazole (88.2%, median 0.55 year) and/or praziquantel (61.8%; median 0.96 year), corticosteroids (88.2%, median 1.09 years), methotrexate (50%, median 1.37 years), and etanercept (34.2%, median 0.81 year), which led to sustained inactive disease in 29/30 (96.7%) patients. Three were treated successfully for recurrences and one has continuing infection. Normalization of cerebral spinal fluid parameters and cestode antigen levels guided treatment decisions. All 15 patients with undetectable cestode antigen values have sustained inactive disease. There were no deaths and moderate morbidity posttreatment. Corticosteroid-related side effects were common, avascular necrosis of joints being the most serious (8/33, 24.2%). Prolonged cysticidal treatment and effective control of inflammation led to good clinical outcomes and sustained inactive disease which is likely curative.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0436
2019-10-21
2020-08-07
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/1/tpmd190436.html?itemId=/content/journals/10.4269/ajtmh.19-0436&mimeType=html&fmt=ahah

References

  1. Garcia HH, Nash TE, Del Brutto OH, 2014. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol 13: 12021215.
    [Google Scholar]
  2. Pittella JE, 1997. Neurocysticercosis. Brain Pathol 7: 681693.
    [Google Scholar]
  3. Henneberg R, 1912. Die tierischen parasiten des zentralnerven-systems. Lewandowsky M, ed. Handbuch der Neurologie. Berlin, Germany: Verlag Von Julius Springer, 643712.
    [Google Scholar]
  4. Valkounova J, Zdarska Z, Slais J, 1992. Histochemistry of the racemose form of Cysticercus cellulosae. Folia Parasitol (Praha) 39: 207226.
    [Google Scholar]
  5. Brown WJ, Voge M, 1982. Neuropathology of Parasitic Infections. Oxford, United Kingdom: Oxford University Press.
    [Google Scholar]
  6. Escobar A, 1983. Pathology of the nervous system. Palacios E, Rodriguez-Carbajal J, Taveras JM, eds. Cysticercosis of the Central Nervous System. Springfield, IL: Charles Thomas, 2754.
    [Google Scholar]
  7. Marquez-Monter H, 1971. Cysticercosis. Marcial-Rojas RA, ed. Pathology of Protozoal and Hleminthic Diseases. Baltimore, MD: The Willimas & Wilkins Company, 592617.
    [Google Scholar]
  8. Zenker FA, 1882. Ueber den Cysticercus racemosus des Gehirns. Beitr Anat Embryolo J Henle Festg 119140.
    [Google Scholar]
  9. Figueroa JJ, Davis LE, Magalhaes A, 2011. Extraparenchymal neurocysticercosis in Albuquerque, New Mexico. J Neuroimaging 21: 3843.
    [Google Scholar]
  10. Bazan R, Hamamoto Filho PT, Luvizutto GJ, Nunes HR, Odashima NS, Dos Santos AC, Elias Junior J, Zanini MA, Fleury A, Takayanagui OM, 2016. Clinical symptoms, imaging features and cyst distribution in the cerebrospinal fluid compartments in patients with extraparenchymal neurocysticercosis. PLoS Negl Trop Dis 10: e0005115.
    [Google Scholar]
  11. Sierra MM et al., 2017. Extraparenchymal neurocysticercosis: demographic, clinicoradiological, and inflammatory features. Plos Negl Trop Dis 11: e0005646.
    [Google Scholar]
  12. Serpa JA, Graviss EA, Kass JS, White AC Jr., 2011. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) 90: 8186.
    [Google Scholar]
  13. Greenfield J, 1958. Infectious Diseases of the Central Nervous System. London, United Kingdom: Edward Arnold Ltd.
    [Google Scholar]
  14. Agapejev S, Meira DA, Barraviera B, Machado JM, Marques PC, Mendes RP, Kamegasawa A, Ueda AK, 1989. Neurocysticercosis: treatment with albendazole and dextrochloropheniramine. Trans R Soc Trop Med Hyg 83: 377383.
    [Google Scholar]
  15. Del Brutto OH et al., 2001. Proposed diagnostic criteria for neurocysticercosis. Neurology 57: 177183.
    [Google Scholar]
  16. Mitre E, Talaat KR, Sperling MR, Nash TE, 2007. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin Infect Dis 44: 549553.
    [Google Scholar]
  17. Nash TE, Ware JM, Coyle CM, Mahanty S, 2019. Etanercept to control inflammation in the treatment of complicated neurocysticercosis. Am J Trop Med Hyg 100: 609616.
    [Google Scholar]
  18. Nash TE, Ware JM, Mahanty S, 2018. Intraventricular neurocysticercosis: experience and long-term outcome from a tertiary referral center in the United States. Am J Trop Med Hyg 98: 17551762.
    [Google Scholar]
  19. Mejia R, Nash TE, 2013. Corticosteroid withdrawal precipitates perilesional edema around calcified Taenia solium cysts. Am J Trop Med Hyg 89: 919923.
    [Google Scholar]
  20. Dixon HBF, Lipscomb FM, 1961. Cysticercosis: An Analysis and Follow up of 450 Cases. Medical Council special report series, no 299. London, United Kingdom: Her Majesty’s Stationary Office, 158.
    [Google Scholar]
  21. Del Brutto OH, 2012. Neurocysticercosis among international travelers to disease-endemic areas. J Trav Med 19: 112117.
    [Google Scholar]
  22. Del Brutto OH, 1992. Cysticercosis and cerebrovascular disease: a review. J Neurol Neurosurg Psychiatry 55: 252254.
    [Google Scholar]
  23. Bickerstaff ER, 1955. Cerebral cysticercosis: common but unfamiliar manifestations. Br Med J 1: 10551058.
    [Google Scholar]
  24. McCormick GF, Giannotta S, Zee C, Fisher M, 1983. Carotid occlusion in cysticercosis. Neurology 33: 10781080.
    [Google Scholar]
  25. Beck ES et al., 2019. Clinicopathology conference: 41-year-old woman with chronic relapsing meningitis. Ann Neurol 85: 161169.
    [Google Scholar]
  26. Callacondo D, Garcia HH, Gonzales I, Escalante D, Nash TE; Cysticercosis Working Group in Peru, 2012. High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis. Neurology 78: 13941400.
    [Google Scholar]
  27. Agapejev S, Da Silva MD, Ueda AK, 1996. Severe forms of neurocysticercosis: treatment with albendazole. Arq Neuropsiquiatr 54: 8293.
    [Google Scholar]
  28. Monteiro L, Almeida-Pinto J, Stocker A, Sampaio-Silva M, 1993. Active neurocysticercosis, parenchymal and extraparenchymal: a study of 38 patients. J Neurol 241: 1521.
    [Google Scholar]
  29. Del Brutto OH, 1997. Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients. J Neurol Neurosurg Psychiatry 62: 659661.
    [Google Scholar]
  30. Cardenas G, Carrillo-Mezo R, Jung H, Sciutto E, Hernandez JL, Fleury A, 2010. Subarachnoidal neurocysticercosis non-responsive to cysticidal drugs: a case series. BMC Neurol 10: 16.
    [Google Scholar]
  31. Gongora-Rivera F, Soto-Hernandez JL, Gonzalez Esquivel D, Cook HJ, Marquez-Caraveo C, Hernandez Davila R, Santos-Zambrano J, 2006. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 66: 436438.
    [Google Scholar]
  32. Del Brutto OH, Sotelo J, Aguirre R, Diaz-Calderon E, Alarcon TA, 1992. Albendazole therapy for giant subarachnoid cysticerci. Arch Neurol 49: 535538.
    [Google Scholar]
  33. Osorio R, Carrillo-Mezo R, Romo ML, Toledo A, Matus C, Gonzalez-Hernandez I, Jung H, Fleury A, 2019. Factors associated with cysticidal treatment response in extraparenchymal neurocysticercosis. J Clin Pharmacol 59: 548556.
    [Google Scholar]
  34. Fleury A, Carrillo-Mezo R, Flisser A, Sciutto E, Corona T, 2011. Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther 9: 123133.
    [Google Scholar]
  35. Proano JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I, 2001. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 345: 879885.
    [Google Scholar]
  36. Virchow R, 1860. Traubenhydatiden der weichen hirnhaut. Archiv für pathologische Anatomie Physiologie klinische Medicin 18: 528535.
    [Google Scholar]
  37. Trelles OJ, Palomino L, 1961. Histopathology of cerebral cysticercosis. Bogaert LV, Kafer JP, Poch GF, eds. Tropical Neurology. Buenos Aires, Argentina: Libreros Editores, 162181.
    [Google Scholar]
  38. Venna N, Coyle CM, Gonzalez RG, Hedley-Whyte ET, 2012. Case 15-2012: a 48-year-old woman with diplopia, headaches, and papilledema. N Engl J Med 366: 19241934.
    [Google Scholar]
  39. Nash TE, Mahanty S, Garcia HH; Cysticercosis Group in Peru, 2011. Corticosteroid use in neurocysticercosis. Expert Rev Neurother 11: 11751183.
    [Google Scholar]
  40. White AC Jr., Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE, 2018. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 66: e49e75.
    [Google Scholar]
  41. Marquez JM, Arauz A, 2012. Cerebrovascular complications of neurocysticercosis. Neurologist 18: 1722.
    [Google Scholar]
  42. Barinagarrementeria F, Cantu C, 1998. Frequency of cerebral arteritis in subarachnoid cysticercosis: an angiographic study. Stroke 29: 123125.
    [Google Scholar]
  43. Barinagarrementeria F, Del BO, 1989. Lacunar syndrome due to neurocysticercosis. Arch Neurol 46: 415417.
    [Google Scholar]
  44. Cantu C, Barinagarrementeria F, 1996. Cerebrovascular complications of neurocysticercosis: clinical and neuroimaging spectrum. Arch Neurol 53: 233239.
    [Google Scholar]
  45. Garcia HH, Gonzales I, Bustos JA, Saavedra H, Gavidia M, Rodriguez L, Najar E, Umeres H, Pretell EJ, 2015. Combined antiparasitic treatment for neurocysticercosis [reply]. Lancet Infect Dis 15: 266267.
    [Google Scholar]
  46. Fleury A, Garcia E, Hernandez M, Carrillo R, Govezensky T, Fragoso G, Sciutto E, Harrison LJ, Parkhouse RM, 2013. Neurocysticercosis: HP10 antigen detection is useful for the follow-up of the severe patients. Plos Negl Trop Dis 7: e2096.
    [Google Scholar]
  47. Fleury A et al., 2007. Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis. J Neurol Neurosurg Psychiatry 78: 970974.
    [Google Scholar]
  48. Garcia HH, Dorny P, Castillo Y, Pretell EJ, Rodriguez S, Mija L, Gonzalez AE, Gilman RH, Tsang VCW, Brandt J, 2010. Antigen levels follow post-treatment evolution of subarachnoid neurocysticercosis. J Neuroparasitol 1: 13.
    [Google Scholar]
  49. Gonzalez AE et al., 2015. Successful antiparasitic treatment for cysticercosis is associated with a fast and marked reduction of circulating antigen levels in a naturally infected pig model. Am J Trop Med Hyg 93: 13051310.
    [Google Scholar]
  50. Bobes RJ, Hernandez M, Marquez C, Fragoso G, Garcia E, Parkhouse RM, Harrison LJ, Sciutto E, Fleury A, 2006. Subarachnoidal and intraventricular human neurocysticercosis: application of an antigen detection assay for the diagnosis and follow-up. Trop Med Int Health 11: 943950.
    [Google Scholar]
  51. Mahanty S, Paredes A, Marzal M, Gonzalez E, Rodriguez S, Dorny P, Guerra-Giraldez C, Garcia HH, Nash T, 2011. Sensitive in vitro system to assess morphological and biochemical effects of praziquantel and albendazole on Taenia solium cysts. Antimicrob Agents Chemother 55: 211217.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0436
Loading
/content/journals/10.4269/ajtmh.19-0436
Loading

Data & Media loading...

Supplemental data and figures

  • Received : 10 Jun 2019
  • Accepted : 12 Aug 2019
  • Published online : 21 Oct 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error